HEBER CITY, Utah , July 25, 2024 /PRNewswire/ -- Renew Biotechnologies , a leading biotech company dedicated to pioneering NGS-based diagnostic solutions, appoints Steven Abbott as Chief Operating Officer (COO). Mr. Abbott brings extensive experience in genomics and biotechnology operations to lead Wasatch BioLabs , a core Renew Biotechnologies subsidiary, from its current research and development phase into full-scale commercial operations.
"We are excited to have Steven Abbott join our executive team at this pivotal point in our development," said Chad Pollard , Co-Founder and CEO of Renew Biotechnologies. "We are building a 20,000 sqft high-throughput clinical laboratory at Wasatch Biolabs to transition to full-scale clinical services. Steven's molecular diagnostics expertise and operational experience will be crucial in this shift.
We are confident his leadership will drive the successful development and launch of our innovative sequencing-based diagnostic tools." Wasatch Biolabs' proprietary nanopore-based sequencing technologies are designed to serve researchers, clinical service providers, and biotech companies, including other Renew portfolio companies . These companies operate across diverse therapeutic areas such as neurodegenerative disease and women's health.
"I am pleased to join Renew Biotechnologies to advance Wasatch Biolabs and other portfolio companies," commented Mr. Abbott. "The unique capabilities of Wasatch Biolabs' novel sequencing technologies present .